세계의 약물 전달 기기 시장 2024-2030 : 용도별 (종양, 전염병), 투여 경로별 (경구, 경피, 주사), 최종 용도별, 지역별

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Route of admission (RoA)
1.1.2. Application
1.1.3. End-use
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interview in North America
1.3.5.2. Data for primary interview in Europe
1.3.5.3. Data for primary interview in Asia Pacific
1.3.5.4. Data for primary interview in Latin America
1.3.5.5. Data for primary interview in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Route of administration (RoA) outlook
2.2.2. Application outlook
2.2.3. End-use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Drug Delivery Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Growing demand for novel drug delivery devices
3.4.1.2. Increasing prevalence of chronic diseases
3.4.1.3. Technological advancement in drug delivery devices
3.4.1.4. Growing strategic alliances for drug delivery devices
3.4.2. Market restraint analysis
3.4.2.1. Challenges associated with various routes of drug delivery devices
3.4.3. Industry challenges
3.5. Drug Delivery Devices Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Route of Administration (RoA) Estimates & Trend Analysis
4.1. Definition and Scope
4.1.1. Oral
4.1.2. Inhalation
4.1.3. Transdermal
4.1.4. Injectable
4.1.5. Ocular
4.1.6. Nasal
4.1.7. Topical
4.1.8. Others
4.2. RoA Market Share, 2024 & 2030
4.3. Segment Dashboard
4.4. Global Drug Delivery Devices Market by RoA Outlook
4.5. Market Size & Forecast and Trend Analysis, 2018 to 2030 for the following
4.5.1. Oral
4.5.1.1. Market estimates and forecast, by oral, 2018 to 2030 (Revenue, USD Billion)
4.5.2. Inhalation
4.5.2.1. Market estimates and forecast, by inhalation, 2018 to 2030 (Revenue, USD Billion)
4.5.3. Transdermal
4.5.3.1. Market estimates and forecast, by transdermal, 2018 to 2030 (Revenue, USD Billion)
4.5.4. Injectable
4.5.4.1. Market estimates and forecast, by injectable, 2018 to 2030 (Revenue, USD Billion)
4.5.5. Ocular
4.5.5.1. Market estimates and forecast, by ocular, 2018 to 2030 (Revenue, USD Billion)
4.5.6. Nasal
4.5.6.1. Market estimates and forecast, by nasal, 2018 to 2030 (Revenue, USD Billion)
4.5.7. Topical
4.5.7.1. Market estimates and forecast, by tropical, 2018 to 2030 (Revenue, USD Billion)
4.5.8. Others
4.5.8.1. Market estimates and forecast, by others, 2018 to 2030 (Revenue, USD Billion)
Chapter 5. Application Estimates & Trend Analysis
5.1. Definition and Scope
5.1.1. Oncology
5.1.2. Infectious diseases
5.1.3. Respiratory disease
5.1.4. Diabetes
5.1.5. Cardiovascular disease
5.1.6. Autoimmune disease
5.1.7. Central nervous system disorders
5.1.8. Others
5.2. Application Market Share, 2024 & 2030
5.3. Segment Dashboard
5.4. Global Drug Delivery Devices Market by Application Outlook
5.5. Market Size & Forecast and Trend Analysis, 2018 to 2030 for the following
5.5.1. Oncology
5.5.1.1. Market estimates and forecast, by oncology, 2018 to 2030 (Revenue, USD Billion)
5.5.2. Infectious disease
5.5.2.1. Market estimates and forecast, by infectious disease, 2018 to 2030 (Revenue, USD Billion)
5.5.3. Respiratory disease
5.5.3.1. Market estimates and forecast, by respiratory disease, 2018 to 2030 (Revenue, USD Billion)
5.5.4. Diabetes
5.5.4.1. Market estimates and forecast, by diabetes, 2018 to 2030 (Revenue, USD Billion)
5.5.5. Cardiovascular diseases
5.5.5.1. Market estimates and forecast, by cardiovascular diseases, 2018 to 2030 (Revenue, USD Billion)
5.5.6. Autoimmune disease
5.5.6.1. Market estimates and forecast, by autoimmune disease, 2018 to 2030 (Revenue, USD Billion)
5.5.7. Central nervous system disorders
5.5.7.1. Market estimates and forecast, by central nervous system disorders, 2018 to 2030 (Revenue, USD Billion)
5.5.8. Others
5.5.8.1. Market estimates and forecast, by others, 2018 to 2030 (Revenue, USD Billion)
Chapter 6. End-use Estimates & Trend Analysis
6.1. Definition and Scope
6.1.1. Hospitals
6.1.2. Diagnostic centers
6.1.3. Ambulatory surgery centers/clinics
6.1.4. Home care settings
6.1.5. Others
6.2. End-use Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. Global Drug Delivery Devices Market by End-use Outlook
6.5. Market Size & Forecast and Trend Analysis, 2018 to 2030 for the following
6.5.1. Hospital
6.5.1.1. Market estimates and forecast, by hospital, 2018 to 2030 (Revenue, USD Billion)
6.5.2. Diagnostic centers
6.5.2.1. Market estimates and forecast, by diagnostic centers, 2018 to 2030 (Revenue, USD Billion)
6.5.3. Ambulatory surgery centers/clinics
6.5.3.1. Market estimates and forecast, by ambulatory surgery centers/clinics, 2018 to 2030 (Revenue, USD Billion)
6.5.4. Home care settings
6.5.4.1. Market estimates and forecast, by home care settings, 2018 to 2030 (Revenue, USD Billion)
6.5.5. Others
6.5.5.1. Market estimates and forecast, by others, 2018 to 2030 (Revenue, USD Billion)
Chapter 7. Drug Delivery Devices Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Regional Market Share and Leading Players, 2019
7.4.1. North America
7.4.2. Europe
7.4.3. Asia Pacific
7.4.4. Latin America
7.4.5. Middle East & Africa
7.5. SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East & Africa
7.6. Market Size & Forecast, Volume & Trend Analysis, 2018 to 2030
7.7. North America
7.7.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Billion)
7.7.2. U.S.
7.7.2.1. Key country dynamics
7.7.2.2. Competitive scenario
7.7.2.3. Regulatory framework
7.7.2.4. Reimbursement structure
7.7.2.5. U.S. market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.7.3. Canada
7.7.3.1. Key country dynamics
7.7.3.2. Competitive scenario
7.7.3.3. Regulatory framework
7.7.3.4. Reimbursement structure
7.7.3.5. Canada market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8. Europe
7.8.1. UK
7.8.1.1. Key country dynamics
7.8.1.2. Competitive scenario
7.8.1.3. Regulatory framework
7.8.1.4. Reimbursement structure
7.8.1.5. UK market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.2. Germany
7.8.2.1. Key country dynamics
7.8.2.2. Competitive scenario
7.8.2.3. Regulatory framework
7.8.2.4. Reimbursement structure
7.8.2.5. Germany market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.3. France
7.8.3.1. Key country dynamics
7.8.3.2. Competitive scenario
7.8.3.3. Regulatory framework
7.8.3.4. Reimbursement structure
7.8.3.5. France market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.4. Italy
7.8.4.1. Key country dynamics
7.8.4.2. Competitive scenario
7.8.4.3. Regulatory framework
7.8.4.4. Reimbursement structure
7.8.4.5. Italy market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.5. Spain
7.8.5.1. Key country dynamics
7.8.5.2. Competitive scenario
7.8.5.3. Regulatory framework
7.8.5.4. Reimbursement structure
7.8.5.5. Spain market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.6. Denmark
7.8.6.1. Key country dynamics
7.8.6.2. Competitive scenario
7.8.6.3. Regulatory framework
7.8.6.4. Reimbursement structure
7.8.6.5. Denmark market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.7. Sweden
7.8.7.1. Key country dynamics
7.8.7.2. Competitive scenario
7.8.7.3. Regulatory framework
7.8.7.4. Reimbursement structure
7.8.7.5. Sweden market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.8.8. Norway
7.8.8.1. Key country dynamics
7.8.8.2. Competitive scenario
7.8.8.3. Regulatory framework
7.8.8.4. Reimbursement structure
7.8.8.5. Norway market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.9. Asia Pacific
7.9.1. Japan
7.9.1.1. Key country dynamics
7.9.1.2. Competitive scenario
7.9.1.3. Regulatory framework
7.9.1.4. Reimbursement structure
7.9.1.5. Japan market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.9.2. China
7.9.2.1. Key country dynamics
7.9.2.2. Competitive scenario
7.9.2.3. Regulatory framework
7.9.2.4. Reimbursement structure
7.9.2.5. China market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.9.3. India
7.9.3.1. Key country dynamics
7.9.3.2. Competitive scenario
7.9.3.3. Regulatory framework
7.9.3.4. Reimbursement structure
7.9.3.5. India market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.9.4. Australia
7.9.4.1. Key country dynamics
7.9.4.2. Competitive scenario
7.9.4.3. Regulatory framework
7.9.4.4. Reimbursement structure
7.9.4.5. Australia market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.9.5. South Korea
7.9.5.1. Key country dynamics
7.9.5.2. Competitive scenario
7.9.5.3. Regulatory framework
7.9.5.4. Reimbursement structure
7.9.5.5. South Korea market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.9.6. Thailand
7.9.6.1. Key country dynamics
7.9.6.2. Competitive scenario
7.9.6.3. Regulatory framework
7.9.6.4. Reimbursement structure
7.9.6.5. Thailand market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.10. Latin America
7.10.1. Brazil
7.10.1.1. Key country dynamics
7.10.1.2. Competitive scenario
7.10.1.3. Regulatory framework
7.10.1.4. Reimbursement structure
7.10.1.5. Brazil market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.10.2. Mexico
7.10.2.1. Key country dynamics
7.10.2.2. Competitive scenario
7.10.2.3. Regulatory framework
7.10.2.4. Reimbursement structure
7.10.2.5. Mexico market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.10.3. Argentina
7.10.3.1. Key country dynamics
7.10.3.2. Competitive scenario
7.10.3.3. Regulatory framework
7.10.3.4. Reimbursement structure
7.10.3.5. Argentina market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.11. MEA
7.11.1. South Africa
7.11.1.1. Key country dynamics
7.11.1.2. Competitive scenario
7.11.1.3. Regulatory framework
7.11.1.4. Reimbursement structure
7.11.1.5. South Africa market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.11.2. Saudi Arabia
7.11.2.1. Key country dynamics
7.11.2.2. Competitive scenario
7.11.2.3. Regulatory framework
7.11.2.4. Reimbursement structure
7.11.2.5. Saudi Arabia market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.11.3. UAE
7.11.3.1. Key country dynamics
7.11.3.2. Competitive scenario
7.11.3.3. Regulatory framework
7.11.3.4. Reimbursement structure
7.11.3.5. UAE market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
7.11.4. Kuwait
7.11.4.1. Key country dynamics
7.11.4.2. Competitive scenario
7.11.4.3. Regulatory framework
7.11.4.4. Reimbursement structure
7.11.4.5. Kuwait market estimates and forecasts, 2018 – 2030 (Revenue, USD Billion)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Innovators
8.2.2. Market Lenders
8.2.3. Emerging Players
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.4. Public Companies
8.4.1. Company market position analysis (Revenue, geographic, presence, product portfolio, key serviceable industries, key alliance
8.4.2. Company market share/ranking, by region
8.4.3. Competitive dashboard analysis
8.4.3.1. Market differentiators
8.4.3.2. Synergy analysis: major deals and strategic alliances
8.5. Private Companies
8.5.1. List of key emerging companies/technology disruptors/innovators
8.5.2. Funding outlook
8.5.3. Regional network map
8.5.4. Company market position analysis (Geographic, presence, product portfolio, key alliance, industry experience)
8.6. Suppliers Ranking
8.7. Key Companies Profiled
8.7.1. Pfizer, Inc,
8.7.1.1. Company overview
8.7.1.2. Financial performance
8.7.1.3. Product benchmarking
8.7.1.4. Strategic initiatives
8.7.2. F. Hoffmann-La Roche Ltd.
8.7.2.1. Company overview
8.7.2.2. Financial performance
8.7.2.3. Product benchmarking
8.7.2.4. Strategic initiatives
8.7.3. Johnson and Johnson Services
8.7.3.1. Company overview
8.7.3.2. Financial performance
8.7.3.3. Product benchmarking
8.7.3.4. Strategic initiatives
8.7.4. Novartis AG
8.7.4.1. Company overview
8.7.4.2. Financial performance
8.7.4.3. Product benchmarking
8.7.4.4. Strategic initiatives
8.7.5. Bayer AG
8.7.5.1. Company overview
8.7.5.2. Financial performance
8.7.5.3. Product benchmarking
8.7.5.4. Strategic initiatives
8.7.6. BD
8.7.6.1. Company overview
8.7.6.2. Financial performance
8.7.6.3. Product benchmarking
8.7.6.4. Strategic initiatives
8.7.7. Uniqure N.V.
8.7.7.1. Company overview
8.7.7.2. Financial performance
8.7.7.3. Product benchmarking
8.7.7.4. Strategic initiatives
8.7.8. SiBiono GeneTech Co.
8.7.8.1. Company overview
8.7.8.2. Financial performance
8.7.8.3. Product benchmarking
8.7.8.4. Strategic initiatives
8.7.9. Shanghai Sunway Biotech Co., Ltd
8.7.9.1. Company overview
8.7.9.2. Financial performance
8.7.9.3. Product benchmarking
8.7.9.4. Strategic initiatives
8.7.10. Human Stem Cells Institute
8.7.10.1. Company overview
8.7.10.2. Financial performance
8.7.10.3. Product benchmarking
8.7.10.4. Strategic initiatives